There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn this the hard way is Wave Life Sciences, which
Recordati says it’s received a $12B+ takeover bid
Milan-based Recordati confirmed Thursday that it has received a buyout offer north of $12 billion. The company said in a press release that private equity


